Tag: RSUs

Vancouver, BC, June 12, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) has granted an aggregate 47,013 stock options, exercisable at $0.71 per share and valid for a term of three years, and an aggregate 514,801 restricted share units, valid for a term between one to three years, to consultants and employees of the Company and its subsidiaries.  The stock options and restricted share units are issued pursuant to the Company’s share compensation plans and are subject to a statutory hold period of four months and one day from issuance, in addition to vesting provisions.

Additionally, and further to the Company’s news release dated July 18, 2025, the Company has extended the marketing services provided by 45 Degrees, Inc. (“45 Degrees”) and Investment Publishing LLC (“Investment Publishing”) to provide digital marketing and investor awareness services until September 30, 2026. No additional compensation shall be payable to 45 Degrees or Investment Publishing for the additional services provided.

GREENVILLE, South Carolina, June 09, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) announces that its Board of Directors has appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange (the “TSXV” or the “Exchange”), including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures.

Highlights:

BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,360 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan, as amended, as a material inducement to employment.